Document is current
Any future updates will be listed below
-
Authors
Agbavor, Bernadette
Arthur, Rejoice Agyeiwaa
Agbanyo, Abigail
Ahiatrogah, Dzifa Kofi
Akenten, Charity Wiafe
Adu-Asiamah, Cynthia
Abass, Kabiru Mohammed
Ofori, Elizabeth
Amofa, George
Boampong, Kwadwo
Thye, Thorsten
Dekker, Denise
Addo, Mathew Glover
Wansbrough-Jones, Mark
Bull, Tim John
Amoako, Yaw Ampem
Phillips, Richard Odame
-
Funding
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (Burulinox TMA 2016 SF-1509, Burulinox TMA 2016 SF-1509)
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 17 February 2025
First Online: 5 March 2025
Declarations
:
: was sought from the Committee on Human Research, Publications and Ethics (CHRPE) (CHRPE/AP/472/17) of the Kwame Nkrumah University of Science and Technology (KNUST). Written informed consent was obtained from willing participants. Full disclosure and explanation of the study procedures was provided to all participants in a language of their choice (this was largely English or the local language, Twi). For individuals who could not read or understand English, consenting was done via an interpreter in the presence of a witness of the individual’s choice. Following this, persons could sign or were thumb-printed to provide consent for inclusion in the study. For young children (< 18 years), written consent was obtained from parents or legal guardians. All the study processes were conducted in accordance with the principles guiding research in human subjects as set out in the Declaration of Helsinki [].
: Not applicable.
: The authors declare no competing interests.
: Not applicable.
